Abbott's freestyle libre® 2 receives national reimbursement in france for all people with diabetes who use insulin¹

First and only continuous glucose monitoring system to be nationally reimbursed in france for people who use once-daily (basal) insulin1 expanded reimbursement facilitates wider access to continuous glucose monitoring (cgm) systems, serving a greater population of people living with diabetes france is the first country in europe to grant national reimbursement for people who use basal insulin, following similar reimbursement expansions in japan and the u.s. (medicare) abbott park, ill., june 22, 2023 /prnewswire/ -- abbott (nyse: abt) today announced that the french health authority has approved the expansion of reimbursement coverage for its freestyle libre 2 system to include all people who use basal insulin as part of their diabetes management.
ABT Ratings Summary
ABT Quant Ranking